KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $111.5 million.

  • Alnylam Pharmaceuticals' Income from Continuing Operations rose 23316.5% to $111.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $278.1 million, marking a year-over-year increase of 19997.91%. This contributed to the annual value of $313.7 million for FY2025, which is 21279.49% up from last year.
  • Alnylam Pharmaceuticals' Income from Continuing Operations amounted to $111.5 million in Q4 2025, which was up 23316.5% from $251.1 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Income from Continuing Operations high stood at $251.1 million for Q3 2025, and its period low was -$405.9 million during Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Income from Continuing Operations averaged around -$121.2 million, with its median value being -$156.0 million (2023).
  • Examining YoY changes over the last 5 years, Alnylam Pharmaceuticals' Income from Continuing Operations showed a top increase of 32504.62% in 2025 and a maximum decrease of 29242.7% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Income from Continuing Operations stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then surged by 233.17% to $111.5 million in 2025.
  • Its Income from Continuing Operations was $111.5 million in Q4 2025, compared to $251.1 million in Q3 2025 and -$66.3 million in Q2 2025.